Skip to main content
ENGN
NASDAQ Life Sciences

enGene Q3 Loss Narrows to $0.47/Share; BLA Filing for Detalimogene on Track for 4Q 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.81
Mkt Cap
$121.921M
52W Low
$1.4
52W High
$12.25
52W Position info
29% above low
Off High info
85% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ENGN sits 29% above its 52-week low of $1.4.

Summary

enGene reported Q3 2026 results with a $32.5M net loss and $266.3M in cash, while confirming its BLA filing for detalimogene is on track for 4Q 2026.


Key Events · Earnings and Guidance · ENGN

  • Q3 Net Loss of $32.5M

    Net loss attributable to common shareholders was $32.5 million, or $0.47 per share, for the three months ended July 31, 2026, compared to $29.0 million, or $0.57 per share, a year earlier.

  • Cash Position of $266.3M

    Cash, cash equivalents and marketable securities totaled $266.3 million as of July 31, 2026, providing operational flexibility through the planned BLA filing and precommercial readiness.

  • BLA Filing on Track for 4Q 2026

    The company plans a data update on key regulatory endpoints, a pre-BLA meeting with the FDA, and initiation of the BLA submission for detalimogene all in 4Q 2026, with a potential FDA approval decision in 2027.

  • Surfactant Cohort Cleared

    The detalimogene plus surfactant cohort safety run-in was successfully cleared, and a webinar on preclinical data and cohort enrollment guidance is scheduled for October 15, 2026.


Analysis · ENGN · Life Sciences

enGene reported a Q3 net loss of $32.5 million ($0.47/share) with $266.3 million in cash, and confirmed its pivotal LEGEND data update, pre-BLA meeting, and BLA submission initiation are all planned for 4Q 2026. The company also cleared the surfactant safety run-in and will host a webinar on October 15, 2026. This matters because the BLA filing is the key near-term value driver for detalimogene in BCG-unresponsive NMIBC, and the cash position supports operations through the regulatory milestones.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENGN was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.9M. The 52-week trading range was $1.40 to $12.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENGN - Latest Insights

ENGN
Nov 12, 2026, 11:33 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $2.21
Real-time Price: $2.01 info
Change: -$0.205 (-9%) info
Market Cap: $134.033M info
ENGN
Nov 12, 2026, 6:14 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.89
Real-time Price: $2.01 info
Change: +$0.115 (+6%) info
Market Cap: $134.033M info
ENGN
Nov 12, 2026, 1:39 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $1.82
Real-time Price: $2.01 info
Change: +$0.185 (+10%) info
Market Cap: $134.033M info
ENGN
Sep 08, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $1.81
Real-time Price: $2.01 info
Change: +$0.195 (+11%) info
Market Cap: $134.033M info
ENGN
Jul 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.82
Real-time Price: $2.01 info
Change: +$0.185 (+10%) info
Market Cap: $134.033M info